Virlaza
Cerebremed
Researches
ENG
Researches
28 February 2023
Virlaza® Efficiently Inhibited LPS-induced Acute Lung Injury
22 July 2021
medRxiv | Virlaza™ Inhibits Sars-COV-2-induced Inflammatory Response of Bronchial Epithelial Cells and Pulmonary Fibroblast

17 July 2021
The ScienceGate | Virlaza Inhibits Sars-COV-2-induced Inflammatory Response of Bronchial Epithelial Cells and Pulmonary Fibroblast
4 June 2021
A Case Report | Virlaza™ Improves Cardiopulmonary Recovery of Post-Covid-19 Patient
11 February 2021
Report Virlaza™ in the Context of Lung Inflammation and Fibrosis in COVID-19
LABPEI - Hot News | Virlaza™ inhibit cytokines release from airway epithelial cells in vitro
LABPEI - Hot news | Virlaza™ improves pulmonary, hematological and muscular recovery of post-covid-19 patient
Virlaza
Cerebremed
Development and research of the company "LibiPharm" - "LibiPharm" Israel.
Privacy Policy
© 2023 Calpton SIA. All rights reserved.
We accept
Terms of sale
Contacts